Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study
FILE The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimers disease soared early Wednesday, Sept. 28, 2022, after Japans Eisai Co. said its potential treatment appeared to slow the fatal diseases progress in a late-stage study.
Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s. The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.
Some 6 million people in the U.S. and many more worldwide have Alzheimer’s, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks. Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Biogen shares soar on Alzheimer's drug developmentsA study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Lire la suite »
Biogen shares rally as Alzheimer's drug results show promiseShares of Biogen and Japanese pharmaceutical company Eisai jumped Wednesday after the drug makers said their potential treatment for Alzheimer's showed promise in slowing the fatal disease that afflicts more than 6 million Americans.
Lire la suite »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Lire la suite »
Stocks making the biggest moves premarket: Biogen, Thor Industries, Lyft and moreThese are the stocks posting the largest moves before the bell.
Lire la suite »
Biogen stock increases as Alzheimer's drug shows promise in early results of studyEisai announced results from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Lire la suite »
Alzheimer's drug study yields positive results, say makers Eisai and BiogenAn experimental Alzheimer's drug made by Eisai Co. Ltd. and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
Lire la suite »